The answerAnswerNo. It is an immunotherapy that marks GD2-expressing neuroblastoma cells for immune attack.Sources for this answerQarziba (Dinutuximab beta)emc · SmPC Current selected SmPC · Version 13NHSNHS · NHS medicine guidance